Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity

Detalhes bibliográficos
Autor(a) principal: Camões-Barbosa, A
Data de Publicação: 2019
Outros Autores: Ribeiro, I, Medeiros, L
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.10/2331
Resumo: Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.
id RCAP_f2b881c83eb863872f8b54bd1ba9a971
oai_identifier_str oai:repositorio.hff.min-saude.pt:10400.10/2331
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke SpasticityParesia do Membro Superior Contralateral Após Infiltração de Toxina Botulínica A para Espasticidade Pós-AVCBotulinum toxins type AMuscle weaknessBotulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.Ordem dos MédicosRepositório do Hospital Prof. Doutor Fernando FonsecaCamões-Barbosa, ARibeiro, IMedeiros, L2019-12-05T11:51:05Z2019-01-01T00:00:00Z2019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.10/2331engActa Med Port , 32 (13) 2019 Apr 26[Online ahead of print]1646-075810.20344/amp.11503info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-20T15:53:01Zoai:repositorio.hff.min-saude.pt:10400.10/2331Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:53:16.735219Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
Paresia do Membro Superior Contralateral Após Infiltração de Toxina Botulínica A para Espasticidade Pós-AVC
title Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
spellingShingle Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
Camões-Barbosa, A
Botulinum toxins type A
Muscle weakness
title_short Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_full Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_fullStr Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_full_unstemmed Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_sort Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
author Camões-Barbosa, A
author_facet Camões-Barbosa, A
Ribeiro, I
Medeiros, L
author_role author
author2 Ribeiro, I
Medeiros, L
author2_role author
author
dc.contributor.none.fl_str_mv Repositório do Hospital Prof. Doutor Fernando Fonseca
dc.contributor.author.fl_str_mv Camões-Barbosa, A
Ribeiro, I
Medeiros, L
dc.subject.por.fl_str_mv Botulinum toxins type A
Muscle weakness
topic Botulinum toxins type A
Muscle weakness
description Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-05T11:51:05Z
2019-01-01T00:00:00Z
2019-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.10/2331
url http://hdl.handle.net/10400.10/2331
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Acta Med Port , 32 (13) 2019 Apr 26[Online ahead of print]
1646-0758
10.20344/amp.11503
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130399699369984